Effective August 26, 2022, the medications primaquine, rifapentine (Priftin^®), and rifaximin (Xifaxan^®) have been added to the ADAP formulary to improve treatment options for HIV-related opportunistic infections.

• Primaquine (when combined with clindamycin) is an alternative treatment regimen for Pneumocystis pneumonia (PCP).
• Weekly dosing of rifapentine (Priftin^®) combined with pyridoxine and isoniazid is now the preferred treatment for latent tuberculosis (TB) infection.
• Rifaximin (Xifaxan®) is an oral antibiotic that is not absorbed (remains in the intestines) and is used to treat traveler's diarrhea caused by Escherichia coli, irritable bowel syndrome with diarrhea, and hepatic encephalopathy.

Adding primaquine, rifapentine (Priftin^®), and rifaximin (Xifaxan®) medications to the ADAP formulary provides greater options to ADAP clients in the treatment of opportunistic infections and helps to ensure that ADAP clients receive care consistent with current national guidelines: Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV.

ADAP management requests that you share this information with your clinical leadership team and local prescribers. The ADAP drug formulary has been updated to reflect the addition of primaquine, rifapentine (Priftin®), and rifaximin (Xifaxan®). 

If you have any questions regarding the addition of these medications to the ADAP formulary, please contact James Vo, ADAP Specialist, at (916) 449-5965.

Thank you,

Sharisse Kemp, MSW

ADAP Branch Chief

California Department of Public Health